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Abstract
Background: Women have a lower risk of hepatocellular carcinoma (HCC) than men, and the decreased possibility
of HCC in women is thought to depend on estrogen levels. As a soybean-isoflavone product, genistein has
estrogenic activity in various reproductive tissues, because it mimics 17β-estradiol and binds the estrogen receptor.
Though genistein is a known liver cancer suppressor, its effects have not been studies in long-term experiment,
where genistein is fed to a female animal model of HCC.
Methods: Mice were treated with diethylnitrosamine (DEN) to induce HCC at 2 weeks of age and fed with supplemental
genistein for 5months, from 40 to 62 weeks of age.
Results: The dietary intake of genistein decreased the incidence of HCC and suppressed HCC development. Genistein
induced phospho-AMPK in total liver extracts, Hep3B cells, and Raw 264.7 cells, and phospho-AMPK promoted apoptosis
in liver and Hep3B cells. Moreover, phospho-AMPK down-regulated pro-inflammatory responses and ameliorated liver
damage. A suppressed pro-inflammatory response with increased mitochondrial respiration was concomitantly observed
after genistein treatment.
Conclusions: Genistein-mediated AMPK activation increases hepatocyte apoptosis through energy-dependent caspase
pathways, suppresses the inflammatory response in resident liver macrophages by increased cellular respiration, and
consequently inhibits the initiation and progression of HCC.
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Background
Women have a lower risk of hepatocellular carcinoma
(HCC) than men, and this difference of HCC risk is most
pronounced in individuals who are under 50 years of age
[1]. The decreased incidences of HCC in women is thought
to depend on sex hormone levels, since estrogen suppresses
pro-inflammatory cytokine and hepatocyte growth factor
levels during liver injury and HCC [2, 3]. Estrogen has been
discovered to play a major role in HCC retardation, and
researchers have focused on the effects and mechanism of
action of estrogen as an HCC therapy [4].
As a soybean-isoflavone product, genistein has estro-
genic activity in various reproductive tissues because it
mimics 17β-estradiol and binds the estrogen receptor
[5]. Interestingly, this phytoestrogen is also known to
suppress the growth of gastric and liver cancer cells by
triggering apoptosis [6]. Moreover, a recent study found
that genistein promotes HCC cell death through sup-
pressing glycolysis. Among various ingestible dietary
phytoestrogens, genistein most effectively reduced HCC
risk in patients [7]. However, most experiments have
focused on therapeutic effects in vitro. Limited in vivo
experiments have been performed with genistein, and
few studies have included clinical applications [6].
Genistein activates AMP-activated protein kinase
(AMPK) and subsequently suppresses nuclear factor
kappa B (NF-κB) signaling [8, 9]. In hepatocytes, AMPK
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activation is necessary for energy metabolism, ATP pro-
duction, and mitochondrial biogenesis [10]. After its ac-
tivation by phosphorylation, phospho-AMPK suppresses
the growth of HCC cells [11]. In an early study, the level
of AMPK expression was found to inversely correlate
with HCC risk [12]. Therefore, AMPK has great poten-
tial as a therapeutic target, for HCC prevention and
treatment [13]. AMPK activation induces apoptosis
through the p53 pathway, which exhibits anti-cancer ac-
tivity and negatively correlates with NF-κB activation
[14–17]. AMPK also contributes to oxidative phosphoryl-
ation, which is a major metabolic pathway of normal cells
for energy production [18]. Interestingly, genistein weakens
the pro-inflammatory response by down-regulating inflam-
mation, via AMPK activation and subsequent NF-κB sup-
pression [19]. When genistein induces apoptosis in various
types of cancer cells [6], genistein is expected to suppress
HCC by anti-inflammatory and pro-apoptotic pathways;
however, its long-term effects have not yet been
investigated.
To avoid changeable female-dependent factors, many
research groups have investigated HCC development
using male rodent models. However, recent studies have
suggested that inclusion of both sexes is necessary to
identify potential molecular mechanisms. In present
study, we used a female mouse model after natural ces-
sation of menstrual cycling (menopause), and female
mice were fed with supplemental genistein for 5 months,
from 40 to 62 weeks. This study was necessary because
no long-term experiments of genistein-fed female ani-
mals bearing HCC have been performed. In addition, it
will be useful to compare the results obtained here to
the studies done on male rodent model. In this study,
we focused on the anti-tumor effect of genistein and in-
vestigated key mediators under female condition.
Methods
Animals and treatment
Mice on a C57BL/6 N background were obtained from
Orient Bio (Daejeon, Korea) and housed in a
pathogen-free facility at Chungnam National University
under a standard 12 h light:12 h dark cycle and fed
standard chow with water provided ad libitum. All
mouse experiments were approved and performed in ac-
cordance with the Chungnam Facility Animal Care
Committee. To develop HCC, 2-w-old female mice were
administered diethylnitrosamine (DEN, 25mg/kg body
weight; 73,861; Sigma) in a 0.9% saline solution by i.p.
injection, as shown in previous report [20]. Genistein
was fed (80 mg/kg/day, 2 mg/day) with chow for 5
months from 40 weeks to 62 weeks of their age. The ani-
mals were monitored thereafter by palpation for tumor
formation and killed by cervical dislocation at the indi-
cated time points for serum and liver isolation. Mice
used for experiment were at least 6 for each control and
genistein group.
For acute DEN experiments, mice were administered
DEN (100mg/kg body weight) in a 0.9% saline solution
by i.p. injection, and livers were isolated at the indicated
time points following injection. Ovariectomy was per-
formed 2 weeks before DEN treatment, by incision on
the dorsal midline to reduce pain than ventral side. Mice
were administered genistein in a corn oil by subcutane-
ously (200 mg/kg body weight), each half for morning
and night with 12 h interval and 1 day before DEN injec-
tion. Mice used for experiment were at least 3 for each
group.
Cell culture
All cell culture reagents were purchased from Welgene
(Gyungsan, Korea). Hep3B human hepatocyte cancer cell
and Raw 264.7 mouse kupffer cell were maintained at 37 °
C in a 5% CO2 atmosphere in DMEM (Welgene, LM001–
05) supplemented with 5% (vol/vol) fetal bovine serum,
penicillin (100 U/mol) and streptomycin (100 μg/ml). For
experiments, cells were maintained in a steroid-free con-
dition with phenol free DMEM (Welgene, LM002–05)
media containing 2% charcoal dextran treated-FBS, peni-
cillin (100U/mol) and streptomycin (100 μg/ml). Genis-
tein (LC laboratories, G-6055) and cobalt(II) chloride
hexahydrate (Sigma, C8661) were added every 12 h with
media change. Lipopolysaccharides (LPS, Sigma, L6511)
was added after dissolved in distilled water (100 ng/ml).
All cell experiments were repeated at least 3 times.
Western blotting
Cell and liver samples were homogenized in lysis buffer
(10 mM Tris, pH 7.5, 150 mM NaCl, 1% Triton X-100, 1
mM phenylmethylsulfonyl fluoride, 0.2 mM sodium
orthovanadate, 0.5% Nonidet P-40 containing protease
inhibitor phenylmethylsulfonyl fluoride (P7626;
Sigma-aldrich, St. Louis, MO, USA) at 4 °C for 15 mins.
TissueLyser II (Qiagen, Hilden, Germany) and sonicator
(Qsonica, Newtown, CT, USA) were used for protein
lysis. Protein was quantified using the Bradford assay
(PRO-MEASURE, Intron Biotechnology, sungnam,
Korea) at 595 nm and proteins were resolved on 5–12%
SDS-PAGE gels (Running buffer: 25 mM Tris, 192 mM
Glycine, 0.1% SDS, and D.W.). After electrophoresis, gels
were blotted with a PVDF membrane (IPVH 00010,
millipore) at 350 mA for 1–2 h with transfer buffer (25
mM Tris, 192 mM Glycine, 20% (v/v) Methanol, and 3rd
D.W.). The membranes were then blocked for 1 h in
PBS containing 0.1% Tween 20 (PBS-T) and 5% skim
milk, and then incubated in tube rotator for overnight at
4 °C with primary antibodies (see below) in the 3% BSA
buffer (1:1000–1:2500). Membranes were then washed
three times in PBS-T for 30 mins to remove excess
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antibody and then incubated for overnight at 4 °C with
secondary antibodies in PBS-T + 5% skim milk (1:5000–
1:10000): mouse anti-rabbit (bs-0295G-HRP; MA, USA
or 211–032-171; Jackson laboratories Inc., PA, USA) or
goat anti-mouse (115–035-174; Jackson laboratories Inc.,
PA, USA). Following 3 washes in PBS-T, immunoreac-
tive proteins were detected by using Ultra 2.0 Western
Blotting substrate (XLS075,1000, Cyanagen) ECL solu-
tion. All buffers used for phospho-protein were based on
TBS and BSA, rather than PBS and Skim milk.
Primary antibodies used were: Cleaved Cas-3, Cas-3
(CST, #9930 T), PARP (CST, #9532), Actin (sc-1616,
Santa cruz), P-AMPK, AMPK (CST, #9957), and p53
(Abnova, PAB12719).
Histological and Immunohistological analyses
For histology, livers were fixed in 10% neutral buffered
formalin and processed through serial dehydration steps.
Tissues in paraffin blocks were sectioned by microtome
(RM2135, Leica) at 4 μm. Sections were attached to si-
lane coated slides (5116-20F-C, Muto), stained with
Hematoxylin and Eosin, and examined by light micros-
copy. For immunohistochemistry, slides were antigen re-
trieved with 0.1% sodium citrate buffer (CA2081,
Georgiachem) at 95 °C for 60 mins. After blocking with
3% bovine serum albumin, slides were incubated at 4 °C
overnight with primary antibodies. After 3 times of
PBS-T wash, secondary antibodies were incubated for 1
h, RT. For immune-reactive TUNEL, reagents were
treated at 37 °C for 1 h. After 3 times of PBS-T wash,
slides were mounted in ProLong Gold anti-fade DAPI
reagent (1,674,645, Life technologies) and examined
using a microscope (DMi8, Leica) in dark area. Primary
antibodies used were: Ki67 (GeneTex, GTX16667) and
TUNEL (Roche, 11,684,795,910 In Situ Cell Death
Detection Kit). Secondary antibodies used were:
Anti-rabbit (A21207, Life technologies).
RNA isolation, reverse transcription and qRT-PCR
Total RNA extracts from mouse liver, Hep3B cells, and
Raw 264.7 cells were prepared using the TRIzol® Reagent
(Thermo Fisher Scientific, MA, USA), Chloroform
(C2432, Sigma), Isopropanol (1.09634.1011, Merck), and
DEPC (E174, Amresco). Reverse transcription was per-
formed with 1.5 μg of total RNA and Reverse transcriptase
kit (SG-cDNAS100, Smartgene, United Kingdom) follow-
ing manufacturer’s protocol. Quantitative PCR(real-time
PCR) was carried out using specific primers (Table 1),
Excel Taq Q-PCR Master Mix (SG-SYBR-500, Smartgene)
and Stratagene Mx3000P(Agilent Technologies) equipped
with a 96-well optical reaction plate. Negative controls,
containing water instead of sample cDNA, were used in
each plate. All experiments were run in triplicate and
mRNA values were calculated based on the cycle thresh-
old and monitored for a melting curve.
Mitochondrial stress test
Raw 264.7 cells were grown in DMEM, 10% FBS, and 1%
penicillin/streptomycin media and incubated with steroid
starvation media (w/o phenol red, 2% CD-FBS, 1% penicil-
lin/streptomycin) for 24 h. After removing endogenous
steroid hormones, genistein (1 μM) was treated for 18 h.
To remove the carbon sources and buffering agents from
the cell media, cells were incubated in non-sodium bicar-
bonate media in non-CO2 incubator in 37 °C, 1 h. Cells
were then proceeded to Seahorse XFp Extracellular Flux
Analyzer (Agilent, Korea). Oligomycin (2 μM), FCCP
(0.5 μM), and rotenone/antimycin A (0.5 μM) were used
for analyze. Number of samples used for experiment was
3 for each group.
Statistical analysis
Data are reported as mean ± SEM. Differences between
means were obtained by Student’s t-test and the
one-way ANOVA followed by a Dunnett post analysis
was performed using Graph Pad Software (GraphPad
Inc., San Diego, CA).
Results
Genistein suppresses the development of DEN-induced
HCC in menopausal mice
To develop artificial HCC, diethylnitrosamine (DEN)
was injected to 2-week-old female C57BL/6 mice. At the
age of 40 weeks, some mice were randomly fed genistein
(Fig. 1a). After 5 months of feeding, the dietary intake of
genistein remarkably reduced the incidence of HCC in
62-week-old mice. Representative images of livers from
control and genistein groups are shown in Fig. 1b. Pyk-
notic nuclei observed in aggregated tumor cells were
easily recognized by dark hematoxylin staining (Fig. 1b).
The tumors presented white-to-yellow nodules, and the
ratio of tumor burden per liver significantly decreased in
the genistein group (13.2%, p < 0.05), relative to the con-
trol group (Fig. 1c). The HCC incidence rate significantly
reduced in the genistein group (53.3%, p < 0.05), com-
pared to the control group, although there was not a sig-
nificant decrease in tumor number (Fig. 1c). As liver
weight increases due to HCC, the ratio of liver weight
per body weight also significantly decreased in the genis-
tein group (88.8%, p < 0.05), compared to the control
group (Fig. 1c).
Genistein increases phospho-AMPK in whole liver,
hepatocytes, and macrophages
As an important mediator for inflammation and
apoptosis, we first analyzed AMPK levels, especially
phospho-AMPK, in genistein treated mice. In the
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livers of 62-week-old mice, we observed significant in-
creases (1.82 fold, p < 0.05) of phospho-AMPKα in the
genistein group, compared to the control group
(Fig. 2a). Likewise, we treated a Hep3B cell line with
genistein for 6 h and observed significantly (p < 0.05)
increased levels of phospho-AMPKα at 1 μM (2.61
fold) and 5 μM (3.06 fold) genistein, compared to the
control group (Fig. 2b). Moreover, in mouse macro-
phages (Raw 264.7 cell), phospho-AMPKα levels sig-
nificantly increased (2.13 fold, p < 0.05) in the
genistein treated group (5 μM), compared to the con-
trol group (Fig. 2c). Through these results, we con-
firmed that genistein activates AMPKα to its
phospho-form.
Fig. 1 Dietary intake of genistein delays initiation and suppresses development of HCC. a Schedule of the dietary intake of genistein. HCC
bearing mice were fed genistein with combined chow for 5 months from the age of 40 weeks to 62 weeks. b Representative images showing
HCC development in 62-week-old livers of female control and genistein groups that were DEN-treated mice. Hematoxylin and eosin (H&E)
staining (Scale bar, 20 μm) of liver is presented. Pyknotic nuclei in tumor cell is stained with dark hematoxylin. c Tumor burden (mm2) quantified
by Image J, incidence, numbers, and liver weight per body weight in 62-week-old livers of female control and genistein groups. Values represent
means ± SEM. *, p < 0.05. Numbers of mice used in experiment is at least each 6 for control and genistein groups
Table 1 Primers used for real-time or conventional PCR, related to Figs. 3 and 5.
Gene name Upper primer (5′ - 3′) Lower primer (5′ - 3′) Species
IκBα TGA AGG ACG AGG AGT ACG AGC TTC GTG GAT GAT TGC CAA GTG Mouse
IL-6 CTG CAA GAG ACT TCC ATC CAG AGT GGT ATA GAC AGG TCT GTT GG Mouse
TNF CCT GTA GCC CAC GTC GTA G GGG AGT AGA CAA GGT ACA ACC C Mouse
Aifm1 TCC AGA GGC CGA AAC AGA G CAT TTT GCC CCC TGA TGA ACC Mouse
Ndufb5 CGA GCT TGC AGA AAT CCC AGA AGG C GTC CAT CAC CTC GGG CAC GCA TCA G Mouse
Rplp0 GCA GCA GAT CCG CAT GTC GCT CCG GAG CTG GCA CAG TGA CCT CAC ACG G Mouse
Bcl2 ATG CCT TTG TGG AAC TAT ATG GC GGT ATG CAC CCA GAG TGA TGC Mouse
Bax TGA AGA CAG GGG CCT TTT TG AAT TCG CCG GAG ACA CTC Mouse
Mdm2 TGT CTG TGT CTA CCG AGG GTG TCC AAC GGA CTT TAA CAA CTT CA Mouse
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Genistein induces apoptosis through an AMPK-mediated
caspase pathway
To investigate whether apoptosis was induced by ge-
nistein anti-cancer activity, we first analyzed levels of
apoptotic markers in the livers of 62-weeks-old mice.
Cleaved PARP showed significantly increased levels
(1.39 fold, p < 0.05) in the livers of the 62-week genis-
tein group, relative to the control group (Fig. 3a).
Cleaved Cas-3 also showed significantly increased
levels (1.4 fold, p < 0.05) in the livers of the 62-week
genistein group, compared to the control group (Fig.
3a). Moreover, the number of terminal deoxynucleoti-
dyl transferase dUTP nick end labeling (TUNEL)
positive signals, which is indicative of apoptosis,
increased (3.12 fold, p < 0.05) in the genistein group,
relative to the control group, when the TUNEL
signals were divided by the number of positive signals
for 4′, 6-diamidino-2-phenylindole (DAPI), which is a
dye that labels the nucleus (Fig. 3b). The mRNA level
of Bax increased (2.65 fold) and that of Bcl2
decreased (73.2%) in the genistein group (p < 0.05,
Fig. 3c). The ratio between Bax and Bcl2, which an
apoptosis marker, significantly increased (3.62 fold, p
< 0.05) in the genistein group, relative to the control
group (Fig. 3c). Furthermore, the level of Mdm2, a
p53 transcriptional repressor, also significantly de-
creased (37%, p < 0.05) in the genistein group, com-
pared to the control group (Fig. 3c).
Fig. 2 Increased levels of phospho-AMPKα in liver of 62-week-old mice, Hep3B cell, and Raw 264.7 cell. a Western blot analysis and quantification
of phosphor-AMPKα in liver of 62-week-old mice. Beta actin was used as an internal control. b Western blot analysis and quantification of
phosphor-AMPKα in Hep3B cell line. Beta actin was used as an internal control. Genistein was treated for 6 h after steoid starvation with charcoal
dextran fetal bovine serum (CD-FBS) for overnight. c Western blot analysis and quantification of phospho-AMPKα in Raw 264.7 cell. Beta actin was
used as an internal control. Genistein was treated for 6 h after steroid starvation with CD-FBS for overnight. Values represent means ± SEM of at
least 3 experiments. *, P < 0.05. Numbers of mice used in experiment is at least each 6 for control and genistein groups





Fig. 3 Genistein induces apoptosis through AMPK activation involving caspase pathways. a Western blot analysis and quantification intact PARP,
cleaved PARP, intact Cas-3, and cleaved Cas-3 in livers of 62-week-old mice. Beta actin was used for an internal control. b Immunofluorescence
detection of TUNEL (green) as a marker of apoptosis in livers of control and genistein groups. Nuclei are stained with DAPI (blue). White arrowheads
indicate apoptotic cells (Scale bar, 50 μm). (c) qRT-PCR analysis of apoptotic genes involved in p53 pathway. dWestern blot analysis of phosphor-AMPKα,
p53, intact PARP, and cleaved PARP. Western blot quantification of cleaved PARP in Hep3B cell after treatment of CoCl2 (100 μM) and genistein (1 μM).
Beta actin was used as an internal control. Values represent means ± SEM of at least 3 experiments. *, P< 0.05
Lee et al. BMC Cancer            (2019) 19:6 Page 6 of 12
Since apoptosis is important for hepatocytes, we made
use of a Hep3B in vitro system to investigate effects of ge-
nistein on hepatocyte apoptosis. While the level of
phospho-AMPKα increased (1.89 fold, p < 0.05) upon
CoCl2 + genistein, relative to the than CoCl2 group, the
level of p53 also increased (1.4 fold, p < 0.05) concomitantly
in the CoCl2 + genistein group (Additional file 1: Figure S1).
Accordingly, the level of cleaved PARP, an executioner of
apoptosis, significantly increased (2.16 fold, p < 0.05) in the
CoCl2 group, relative to the control group (Fig. 3d), and
further increased (1.15 fold, p < 0.05) in the CoCl2 + genis-
tein group, relative to the CoCl2 group (Fig. 3d).
Genistein suppresses hepatic DEN-induced inflammation
and tumor proliferation
Next, we analyzed the level of the inflammatory
markers that are considered as typical accelerants for
HCC initiation. We found that the genistein group
showed significantly decreased (76.5%, p < 0.05) IκBα
mRNA levels than the control group (Fig. 4a), which
suggests that NF-κB, a key player in
pro-inflammation, is suppressed. The mRNA levels of
pro-inflammatory cytokines, IL-6 (68%) and TNF
(76.4%), both significantly (p < 0.05) decreased in the
genistein group, compared to the control group (Fig.
4a). As inflammation triggers tumor proliferation, we
used Ki67 as a proliferation marker and observed sig-
nificant decrease (38.6%, p < 0.05) in the genistein
group, compared to the control group, when Ki67 sig-
nal was divided by the number of DAPI-positive sig-
nals (Fig. 4b).
To evaluate the effects of genistein in acute hepatic
injury, we treated mice with DEN (100 mg/kg) for 48
h, after injecting genistein (200 mg/kg) for 24 h.
Ovariectomies were performed to terminate endogen-
ous estrogen, and a subsequent restoration was main-
tained for 2 weeks. In the microscopic analysis of
H&E staining, the DEN group showed markedly dam-
aged regions, while the DEN-genistein group exhib-
ited less damaged areas than the DEN group
(Additional file 1: Figure S2A). This result closely as-
sociated with decreased (79.1%, p < 0.05) alanine ami-
notransferase (ALT) levels in the DEN-genistein
group than in the DEN group, and the disruption of
hepatocytes by DEN injection increased the level of
ALT (1.63 fold, p < 0.05), which is a liver cell damage
marker (Additional file 1: Figure S2B). Furthermore,
the mRNA level of IκBα increased (4.77 fold, p < 0.05)
in DEN the group, compared to the control group,
which implies that the inflammation was triggered by
DEN (Additional file 1: Figure S2B). In contrast,
decreased (47.7%, p < 0.05) IκBα mRNA levels were
observed in the DEN-genistein group, compared to
the DEN group, which implies that the inflammatory
effect was suppressed by genistein (Additional file 1:
Figure S2B).
Fig. 4 Genistein suppressed hepatic inflammation and tumor proliferation. (a) qRT-PCR analysis of IκBα and pro-inflammatory cytokines in liver of
62-week-old mice. Rplp0 was used for an internal control. (b) Ki67 positive cells (pink) are shown. Nuclei are stained with DAPI (blue). White arrowheads
indicate proliferating cells (Scale bar, 50 μm). Ki67 per DAPI (%) in tumor area of control and genistein groups. Values represent means ± SEM of at least 3
experiments. *, P< 0.05
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Genistein promotes mitochondrial respiration in
macrophages through AMPK activation
As pro-inflammatory cytokine levels were decreased by
genistein, we hypothesized that genistein triggers an
anti-inflammatory macrophage state of by inducing
mitochondrial respiration through AMPK activation. To
investigate how genistein influences macrophage mito-
chondrial respiration, we evaluated the metabolic status
(Oxygen consumption rate, OCR) of Raw 264.7 cells
after genistein treatment (1 μM) for 18 h. As shown in
Fig. 5a, genistein treatment triggered the overall induc-
tion of mitochondrial respiration in Raw 264.7 cells.
First, the basal respiration level significantly increased in
the genistein group (1.45 fold, p < 0.05), compared to the
control group (Additional file 1: Figure S3A-A). When
we blocked ATP synthase with oligomycin, we observed
increased ATP production levels (1.45 fold, p < 0.05) in
the genistein group, compared to the control group
(Additional file 1: Figure S3A-B). Moreover, increased
proton leak levels were observed in the genistein group
(1.44 fold), relative to the control group, which indicated
the uncoupling of non-mitochondrial respiration, similar to
the effects observed with rotenone/antimycin A (Additional
file 1: Figure S3A-C, E). In the presence of
p-trifluoromethoxyphenylhydrazone (FCCP), which blocks
mitochondrial respiration, a huge rise in oxygen consump-
tion rate was observed in the genistein group, relative to
the control group, which suggests that maximal respiration
(1.73 fold) and spare respiratory capacity (2.32 fold) consid-
erably increase after genistein treatment (p < 0.05, Add-
itional file 1: Figure S3A-D, F).
The induction of oxidative phosphorylation conse-
quently led to a reduced pro-inflammatory state of Raw
264.7 cells. After 6 h of genistein (1 μM) incubation,
which was similar to lipopolysaccharide (LPS) condition-
ing, we observed significantly (p < 0.05) suppressed levels
of IκBα (87%), IL-6 (81%) and TNF (67%) in the genis-
tein group, compared to the control group (Fig. 5c). This
observation concomitantly occurred with the induction
of phospho-AMPK by genistein (Fig. 5b). Similarly, the
induction of phospho-AMPK was also observed in the
LPS-triggered inflammatory state. After pre-incubation
with genistein for 2 h, Raw 264.7 cells were exposed to
LPS (100 ng/ml) for 3 h, after which the phospho-AMPK
levels significantly increased (1.52 fold, p < 0.05) in the
LPS-genistein group (5 μM), compared to the
LPS-control group (Fig. 5d).
phospho-AMPK may associate with mitochondrial res-
piration through p53, as we observed significantly in-
creased (1.94 fold, p < 0.05) levels of p53 in the
LPS-genistein group (5 μM), relative to the LPS-control
group (Fig. 5e). Following the induction of p53, its down-
stream target, Aifm1, also showed significantly (p < 0.05)
increased (1.74 and 1.55 fold) levels after genistein
treatment (1 μM and 5 μM), compared to the LPS group
(Additional file 1: Figure S4). This result is consistent with
the induction of mitochondrial respiration, as Aif pro-
motes oxidative phosphorylation. As a result, LPS trig-
gered acute inflammation in Raw 264.7 cells and
increased (16.37 fold) IκBα mRNA levels, relative to the
control group, while genistein suppressed (87.5%) inflam-
mation in the LPS group (p < 0.05, Fig. 5e). Moreover, the
mRNA levels of IL-6 (57.9%) and TNF (73%) decreased in
the LPS + genistein group, compared to the LPS group.
These mRNA levels were also induced in the LPS group
(17.8 fold and 69.3 fold), relative to the control group (p <
0.05, Fig. 5e).
Discussion
While HCC occurs predominantly in patients with
underlying chronic liver disease and cirrhosis, genistein
consumption has a high potential to prevent the pro-
gression of severe liver diseases into liver cancer [7]. Nu-
merous studies have investigated genistein and liver
cancer cells in vitro [21, 22]; however, the long-term ef-
fects of genistein on HCC establishment and develop-
ment in vivo remain unclear [23]. Therefore, our study
highlights the effects of dietary genistein intake on
long-standing HCC suppression. We found that genis-
tein suppresses cancer initiation and development
through AMPK-mediated anti-inflammation and
pro-apoptosis.
Inflammatory and apoptotic activities in macrophages
and hepatocytes are triggered by characterized signals
during HCC development. In the present study, genis-
tein consistently increased phospho-AMPK levels in
liver, Hep3B cell, and Raw 264.7 cells. AMPK is known
to suppress inflammation, which usually implies poor
prognosis and development of HCC [24], through redu-
cing pro-inflammatory marker and NF-kB levels [25].
NF-kB is the main contributor to hepatocarcinogenesis
with chronic inflammation and functions through indu-
cing the levels of growth factors and compensatory
regeneration [26]. Subsequent to NF-kB stimulation,
the release of inflammatory cytokines leads to the
proliferation and survival of cancer cells, which pro-
motes cancer development [27]. In the present study,
genistein down-regulated TNF and IL-6, among the
pro-inflammatory cytokines secreted by NF-kB signal-
ing. TNF is implicated with cellular proliferation in
hepatocarcinogenesis and persistent IL-6 is associated
with tumor development [28, 29]. Through our result
of Ki67 immunofluorescence analysis, which is a
marker for vigorous cancer cell mitosis, we observed
that genistein consequently suppressed the prolifera-
tion of cancer cells [30].
Importantly, genistein promoted anti-cancer apoptotic
activity by inducing phospho-AMPK. Contrary to
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inflammation, apoptosis is a programmed cell death path-
way that suppresses cancer activity [31]. Therefore, the
down-regulation of anti-apoptotic factors through HCC
therapy can suppress the growth of cancer cells [32]. As a
tumor suppressor gene that reacts with stress responses
and contains anti-proliferative activity, p53 regulates the
transcription of apoptotic effector genes and consequently
induces caspases to promote apoptosis [33]. AMPK is also
involved with p53 in apoptosis [15], and we observed p53
induction and AMPK phosphorylation by genistein. More-
over, we observed that genistein increased the level of Bax
and decreased the level of Bcl2 in the present study, which
are known to be involved in the p53 pathway [34]. The de-
creased level of Mdm2 was also consistent with the in-
creased level of p53, as Mdm2 is a repressor of
p53-mediated apoptosis [35]. More importantly, the in-
creased level of p53 by genistein consequently led to the
induction of apoptotic markers. As an executioner for
apoptosis [36], the level of cleaved Cas-3 and cleaved
PARP increased upon genistein treatment. The increased
number of positive TUNEL signals upon genistein treat-
ment also demonstrates the promotion of apoptosis [37].
Interestingly, we found that the apoptotic effect of genis-
tein involves AMPK phosphorylation, and a recent study
found that genistein has a synergistic effect with sorafenib,
which induces apoptosis in HCC cells [38].
Furthermore, we observed that genistein increased
mitochondrial function in Raw 264.7 cells through the
induction of phospho-AMPK and p53. AMPK is
known to induce mitochondrial respiration, and p53
also ensures mitochondrial function through Aif-1 in-
duction, by sensitizing oxidative phosphorylation
when apparent apoptotic signs are minimal [39]. In
our seahorse data, we observed increased mitochon-
drial ATP production and Aif-1 levels upon the in-
duction of p53. Considering that increased oxidative
phosphorylation attenuates pro-inflammatory macro-
phage responses, and mitochondrial dysfunction pre-
vents repolarization to anti-inflammatory M2
macrophages [40–42], these results are consistent
with the down-regulation of pro-inflammatory cyto-
kines in Raw 264.7 cells and suggests that genistein
induces the anti-inflammatory state of macrophages.
In addition, the increased p53 levels in Raw 264.7
cells upon genistein treatment implies that AMPK is
consistently involved in oxidative phosphorylation, as
AMPK induces p53 and promotes macrophage
polarization to an anti-inflammatory state [42]. For
cancer therapy, mitochondrial oxidative phosphoryl-
ation increases the sensitivity of HCC to drugs [43],
and the decrease in glycolysis leads to HCC suppres-
sion [44]. A previous study has suggested that genis-
tein reinforces cisplatin activity [45], and our study
also suggests the potential of genistein to improve or
sensitize the action of HCC drugs.
According to the present study, the long-term dietary
intake of genistein remarkably suppresses hepatocarcino-
genesis and hepatocellular carcinoma development
through AMPK activation. Phosphorylated AMPK plays
potential roles in anti-inflammation, pro-apoptotic, and
pro-oxidative phosphorylation process in HCC. While
chemotherapy still exerts severe damage to the host, the
dietary intake of genistein is highly valuable for HCC
prevention, when intake is consistent and maintained for
long time, since genistein does not have an immediate
effect.
Conclusions
Our study reveals the long-term effects of dietary genis-
tein intake, which prevents the initiation and suppresses
the development of HCC, through mechanisms involv-
ing AMPK.
Additional file
Additional file 1: Figure S1. Western blot quantification of pAMPKα
and p53 in Hep3B cell. CoCl2+genistein group showed significant
increase (1.89 fold and 1.4 fold, p<0.05) than CoCl2 group in mRNA level
of pAMPKα and p53. Beta actin was used for an internal control. CoCl2
(100μM) and genistein (1μM) were treated for 48 hrs after steroid
starvation for overnight. Values represent means ± SEM of at least 3
experiments. *, P<0.05. Figure S2. Genistein ameliorated acute hepatic
injury by DEN treatment. DEN was treated (100mg/kg) for 48 hrs after
injecting genistein (200mg/kg) for 24 hrs previously. Ovariectomy was
performed to terminate endogenous estrogen, and subsequent
restoration was maintained for 2 weeks. (A) Hematoxylin & eosin staining
(Scale bar, 200μm) of liver was presented. DEN showed remarkarbly
increased damage area while genistein suppressed it. (B) qRT-PCR analysis
of IκBα is presented. DEN group showed significant increase (4.77 fold,
p<0.05)in mRNA level of IκBα than vehicle group. DEN-genistein grouop
showed significant decrease (47.7%, p<0.05) in mRNA level of IκBα than
DEN group. Rplp0 was used for an internal control. As a hepatic damage
marker, ALT level (U/I) showed significant increase (1.63 fold, p<0.05) in
DEN group than vehicle group. DEN-genistein grouop showed significant
decrease (79.1%, p<0.05) in ALT level than DEN group. Values represent
means ± SEM of at least 3 experiments. *, P<0.05. Figure S3. Overall in-
creased levels of oxygen consumption rate (OCR, pmol/min) for each
Fig. 5 Genistein induced mitochondrial respiration and suppressed pro-inflammatory state in macrophage. a Mitochondrial respiration analysis of
control and genistein groups (1 μM, 18 h). A: Basal respiration, B: ATP production, C: Proton Leak, D: Maximal respiration, E: Non-mitochondrial
respiration, F: Spatial respiratory capacity. b Western blot analysis and quantification of phospho-AMPKα. Genistein (1 μM) was treated for 6 h. Beta
actin was used as an internal control. (c) qRT-PCR analysis of pro-inflammatory cytokines. Genistein (1 μM) was treated for 6 h. Rplp0 was used as
an internal control. d Western blot analysis and quantification of phospho-AMPKα and p53. LPS (100 ng/ml) was treated for 3 h and genistein
(1 μM) was pre-treated for 2 h. Beta actin was used as an internal control. (e) qRT-PCR analysis of IκBα and pro-inflammatory cytokines in Raw
264.7 cell. Rplp0 was used for an internal control. Genistein (1 μM) was pre-treated 1 h before LPS incubation (100 ng/ml, 3 h). Values represent
means ± SEM of at least 3 experiments. *, P < 0.05
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steps during mitochondrial stress test. Genistein (1μM) was treated for 18
hrs after steroid starvation for overnight. Values represent means ± SEM
of at least 3 experiments. *, P<0.05. Figure S4. Relative mRNA level of
apoptotic gene involved in p53 pathway and oxidative phosphorylation
in Raw 264.7 cell. qRT-PCR analysis of Aifm1 is presented. Rplp0 was used
for an internal control. Genistein (1μM , 5μM) was treated for 6 hrs after
steroid starvation for overnight. Values represent means ± SEM of at least
3 experiments. *, P<0.05. (DOCX 277 kb)
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